{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:43:02Z","timestamp":1788043382262,"version":"build-2784847793"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:sec id=\"ab-doi230022-4\"><jats:title>Importance<\/jats:title><jats:p>The pathogenesis of eosinophilic cellulitis (EC) is poorly understood, limiting available treatment options. The current treatment paradigm focuses on delayed type 2 hypersensitivity reaction to various triggers.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230022-5\"><jats:title>Objective<\/jats:title><jats:p>To gain further insight into the nature of EC inflammation and into the cellular signal transduction pathways that are activated in the context of EC.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230022-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This case series was conducted in Lyon, France, from January 2018 to December 2021. Analysis of archival skin biopsy samples from patients with EC and from healthy control participants was performed using histology, Janus kinase (JAK)\u2013signal transducer and activator of transcription (STAT) immunohistochemistry, and gene profiling. Data analysis was conducted between January 2020 and January 2022.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230022-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Pruritus (visual analog score), percentage of body surface area with lesional skin, and RNA transcripts of inflammatory biomarkers from the skin (threshold cycle) were assessed in 1 index patient with refractory EC who received oral JAK1\/JAK2 inhibitor baricitinib (4 mg\/d).<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230022-8\"><jats:title>Results<\/jats:title><jats:p>This study included samples from 14 patients with EC (7 men and 7 women) and 8 healthy control participants (4 men and 4 women). The mean (SD) age of patients was 52\u2009(20) years. Marked type 2 inflammation (chemokines CCL17, CCL18, and CCL26 and interleukin 13) with preferential activation of the JAK1\/JAK2\u2013STAT5 pathways in EC lesions was observed. In the 1 index patient with refractory EC, complete clinical remission of skin lesions was observed after 1 month of treatment with baricitinib.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230022-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>These findings suggest that EC is a type 2 inflammatory disease with preferential activation of the JAK1\/JAK2-STAT5 pathways. In addition, these results suggest the potential of treatment approaches targeting JAK1\/JAK2 for patients with EC.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.1651","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T17:14:34Z","timestamp":1687367674000},"page":"820","source":"Crossref","is-referenced-by-count":16,"title":["Hyperactivation of the JAK2\/STAT5 Signaling Pathway and Evaluation of Baricitinib Treatment Among Patients With Eosinophilic Cellulitis"],"prefix":"10.1001","volume":"159","author":[{"given":"Johanna","family":"Morot","sequence":"first","affiliation":[{"name":"Centre International de Recherche en Infectiologie, Universit\u00e9 Claude Bernard Lyon 1, Inserm U1111, CNRS, UMR5308, ENS Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Del Duca","sequence":"additional","affiliation":[{"name":"Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Chastagner","sequence":"additional","affiliation":[{"name":"Centre International de Recherche en Infectiologie, Universit\u00e9 Claude Bernard Lyon 1, Inserm U1111, CNRS, UMR5308, ENS Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeriel","family":"Estrada","sequence":"additional","affiliation":[{"name":"Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine-Alexia","family":"Lefevre","sequence":"additional","affiliation":[{"name":"Centre International de Recherche en Infectiologie, Universit\u00e9 Claude Bernard Lyon 1, Inserm U1111, CNRS, UMR5308, ENS Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Kanitakis","sequence":"additional","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Edouard Herriot, Hospices Civils de Lyon, Lyon, France"},{"name":"Department of Pathology, H\u00f4pital Lyon-Sud, Hospices Civils de Lyon, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Harou","sequence":"additional","affiliation":[{"name":"Department of Pathology, H\u00f4pital Lyon-Sud, Hospices Civils de Lyon, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Jullien","sequence":"additional","affiliation":[{"name":"Centre International de Recherche en Infectiologie, Universit\u00e9 Claude Bernard Lyon 1, Inserm U1111, CNRS, UMR5308, ENS Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Nicolas","sequence":"additional","affiliation":[{"name":"Centre International de Recherche en Infectiologie, Universit\u00e9 Claude Bernard Lyon 1, Inserm U1111, CNRS, UMR5308, ENS Lyon, Lyon, France"},{"name":"Department of Allergology and Immunology, H\u00f4pital Lyon-Sud, Hospices Civils de Lyon, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Krueger","sequence":"additional","affiliation":[{"name":"Laboratory of Investigative Dermatology, The Rockefeller University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Vocanson","sequence":"additional","affiliation":[{"name":"Centre International de Recherche en Infectiologie, Universit\u00e9 Claude Bernard Lyon 1, Inserm U1111, CNRS, UMR5308, ENS Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[{"name":"Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel P.","family":"Villani","sequence":"additional","affiliation":[{"name":"Centre International de Recherche en Infectiologie, Universit\u00e9 Claude Bernard Lyon 1, Inserm U1111, CNRS, UMR5308, ENS Lyon, Lyon, France"},{"name":"Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"doi230022r1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40257-020-00520-4","article-title":"Eosinophilic dermatoses: recognition and management.","volume":"21","author":"Marzano","year":"2020","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"doi230022r2","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1001\/archderm.142.9.1157","article-title":"Wells syndrome in adults and children: a report of 19 cases.","volume":"142","author":"Caputo","year":"2006","journal-title":"Arch Dermatol"},{"issue":"1","key":"doi230022r3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1046\/j.1365-4362.2003.01705.x","article-title":"Wells\u2019 syndrome: a clinical and histopathologic review of seven cases.","volume":"42","author":"Moossavi","year":"2003","journal-title":"Int J Dermatol"},{"issue":"9","key":"doi230022r4","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/jdv.13706","article-title":"Treatment of eosinophilic cellulitis (Wells syndrome)\u2014a systematic review.","volume":"30","author":"R\u00e4\u00dfler","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"doi230022r5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/ddg.v18.7","article-title":"Effective treatment with mepolizumab in a patient with refractory Wells syndrome.","volume":"18","author":"Terhorst-Molawi","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"doi230022r6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s13555-017-0214-1","article-title":"Dapsone for recalcitrant eosinophilic annular erythema: a case report and literature review.","volume":"8","author":"Wallis","year":"2018","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"doi230022r7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s13555-020-00412-9","article-title":"Mepolizumab therapy for recalcitrant eosinophilic annular erythema in an adult: a case report and review of treatment options.","volume":"10","author":"Zychowska","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"doi230022r8","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.jdcr.2018.02.011","article-title":"Eosinophilic cellulitis (Wells syndrome) successfully treated with mepolizumab.","volume":"4","author":"Herout","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"6","key":"doi230022r9","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.anai.2021.01.035","article-title":"Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis.","volume":"126","author":"Manka","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"doi230022r10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/all.v76.1","article-title":"Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines.","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"issue":"11","key":"doi230022r11","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1111\/ddg.v19.11","article-title":"Dupilumab in eosinophilic cellulitis (Wells\u2019 syndrome)\u2014case report of a potential new treatment option.","volume":"19","author":"Traidl","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"doi230022r12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jaad.2009.08.041","article-title":"High responses of peripheral lymphocytes to mosquito salivary gland extracts in patients with Wells syndrome.","volume":"63","author":"Koga","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi230022r13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.18176\/jiaci","article-title":"Eosinophilic cellulitis possibly due to mosquito bite with high IL-5 production.","volume":"27","author":"Mashima","year":"2017","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"8","key":"doi230022r14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2183\/pjab.87.463","article-title":"Interleukin-5 and IL-5 receptor in health and diseases.","volume":"87","author":"Takatsu","year":"2011","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"3","key":"doi230022r15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s001050051101","article-title":"Eosinophilic cellulitis (Wells syndrome).","volume":"51","author":"Pl\u00f6tz","year":"2000","journal-title":"Hautarzt"},{"issue":"6","key":"doi230022r16","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/S0190-9622(03)00447-X","article-title":"Eosinophilic fasciitis and eosinophilic cellulitis in a patient with abnormal circulating clonal T cells: increased production of interleukin 5 and inhibition by interferon alfa.","volume":"49","author":"French","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"doi230022r17","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"doi230022r18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.4049\/jimmunol.1801629","article-title":"IL-3 receptor expression on activated human Th cells is regulated by IL-4, and IL-3 synergizes with IL-4 to enhance Th2 cell differentiation.","volume":"204","author":"Kumar","year":"2020","journal-title":"J Immunol"},{"issue":"11","key":"doi230022r19","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.4049\/jimmunol.170.11.5359","article-title":"Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression.","volume":"170","author":"Gregory","year":"2003","journal-title":"J Immunol"},{"key":"doi230022r20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.12688\/f1000research","article-title":"STAT5 and CD4+ T cell immunity.","volume":"6","author":"Owen","year":"2017","journal-title":"F1000Res"},{"issue":"11","key":"doi230022r21","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/ni.1656","article-title":"Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor alpha-chain expression.","volume":"9","author":"Liao","year":"2008","journal-title":"Nat Immunol"},{"key":"doi230022r22","doi-asserted-by":"publisher","first-page":"30977","DOI":"10.1038\/srep30977","article-title":"STAT5 is a key transcription factor for IL-3-mediated inhibition of RANKL-induced osteoclastogenesis.","volume":"6","author":"Lee","year":"2016","journal-title":"Sci Rep"},{"issue":"5","key":"doi230022r23","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1182\/blood-2016-09-737817","article-title":"Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea.","volume":"129","author":"Ma","year":"2017","journal-title":"Blood"},{"issue":"2","key":"doi230022r24","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3390\/ijms22020486","article-title":"Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes.","volume":"22","author":"Stella","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"8","key":"doi230022r25","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/leu.2014.89","article-title":"Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.","volume":"28","author":"Kontro","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"doi230022r26","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1038\/leu.2014.200","article-title":"Frequent STAT5B mutations in ?d hepatosplenic T-cell lymphomas.","volume":"28","author":"Nicolae","year":"2014","journal-title":"Leukemia"},{"issue":"22","key":"doi230022r27","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1182\/blood-2012-12-474577","article-title":"Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia.","volume":"121","author":"Rajala","year":"2013","journal-title":"Blood"},{"issue":"1","key":"doi230022r28","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omaa129","article-title":"A case of hypereosinophilic syndrome with STAT5b N642H mutation.","volume":"2021","author":"Ding","year":"2021","journal-title":"Oxf Med Case Reports"},{"issue":"3","key":"doi230022r29","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.","volume":"130","author":"Valent","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"doi230022r30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1006\/bbrc.1996.0674","article-title":"Interleukin 3 activates not only JAK2 and STAT5, but also Tyk2, STAT1, and STAT3.","volume":"221","author":"Nagata","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"doi230022r31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0014-5793(96)00835-6","article-title":"IL4 and IL13 receptors share the gamma c chain and activate STAT6, STAT3 and STAT5 proteins in normal human B cells.","volume":"393","author":"Rolling","year":"1996","journal-title":"FEBS Lett"},{"issue":"6","key":"doi230022r32","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.jaci.2016.12.957","article-title":"JAK1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome.","volume":"139","author":"Del Bel","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"doi230022r33","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.molimm.2004.04.027","article-title":"STAT-1 is activated by IL-4 and IL-13 in multiple cell types.","volume":"41","author":"Wang","year":"2004","journal-title":"Mol Immunol"},{"issue":"1-3","key":"doi230022r34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000053722","article-title":"The role of STAT1 in activation of IL-3- and IL-5-induced eosinophils by interferon gamma.","volume":"124","author":"Ochiai","year":"2001","journal-title":"Int Arch Allergy Immunol"},{"issue":"11","key":"doi230022r35","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1002\/eji.201242433","article-title":"STAT6-dependent and -independent mechanisms in Th2 polarization.","volume":"42","author":"Maier","year":"2012","journal-title":"Eur J Immunol"},{"issue":"4","key":"doi230022r36","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.24635","article-title":"JAK2-STAT5 signaling: a novel mechanism of resistance to targeted PI3K\/mTOR inhibition.","volume":"2","author":"Yeh","year":"2013","journal-title":"JAKSTAT"},{"issue":"4","key":"doi230022r37","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.3892\/mmr","article-title":"IFN-? induces apoptosis in human melanocytes by activating the JAK1\/STAT1 signaling pathway.","volume":"22","author":"Su","year":"2020","journal-title":"Mol Med Rep"},{"key":"doi230022r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114690","article-title":"The JAK1\/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.","volume":"192","author":"Luschnig","year":"2021","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"doi230022r39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"doi230022r40","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3899\/jrheum.200998","article-title":"Successful treatment with baricitinib in a patient with refractory eosinophilic fasciitis.","volume":"48","author":"Sehgal","year":"2021","journal-title":"J Rheumatol"},{"issue":"11","key":"doi230022r41","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1007\/s10067-020-05134-z","article-title":"Hypereosinophilic syndrome\u2014a rare adverse event of anti-cytokine treatment in rheumatoid arthritis resolved after Janus kinase inhibitor therapy.","volume":"39","author":"\u0160tenov\u00e1","year":"2020","journal-title":"Clin Rheumatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2806331\/jamadermatology_morot_2023_oi_230022_1692117341.51479.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T15:02:44Z","timestamp":1692198164000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2806331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.1651","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}